Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pluristem Fast Forwards Placental Cell Therapy Into US-EU Pivotal Trial

Executive Summary

Off-the-shelf placental cell therapy for peripheral artery disease will move from Phase I to registration stage study in US and Europe in early 2017, following “positive feedback” from FDA.

You may also be interested in...



Video: Pluristem Says Its Placental Stem Therapy Offers "Off The Shelf" Promise

Pluristem Therapeutics Chairman and CEO Zami Aberman explains how stem cell therapy will shape the industry, in a recent interview at the Biotech Showcase.

Cell Therapy Developers Debate Challenges As Big Pharma Drags Its Feet

Companies developing 'advanced' treatments such as cell therapies face many of the same challenges in getting their innovative products to market, yet the attitudes of management towards the various hurdles differs quite significantly, Scrip found at Alliance for Regenerative Medicine's third annual 'European Advanced Therapies Investor Day' on Nov. 12.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel